G. Alhatemi, Rafal Alhatemi, H. Aldiwani, Marwah Hussein, E. Levi, P. Jasti
{"title":"高钙血症在晚期前列腺腺癌患者中的意义尚不明确。","authors":"G. Alhatemi, Rafal Alhatemi, H. Aldiwani, Marwah Hussein, E. Levi, P. Jasti","doi":"10.12788/fp.0018","DOIUrl":null,"url":null,"abstract":"Hypercalcemia in the setting of prostate cancer is rare with an uncertain pathophysiology and more research is needed into the role of parathyroid hormone-related peptide as a growth factor and possibly target-directed monoclonal antibody therapies.","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Hypercalcemia Is of Uncertain Significance in Patients With Advanced Adenocarcinoma of the Prostate.\",\"authors\":\"G. Alhatemi, Rafal Alhatemi, H. Aldiwani, Marwah Hussein, E. Levi, P. Jasti\",\"doi\":\"10.12788/fp.0018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hypercalcemia in the setting of prostate cancer is rare with an uncertain pathophysiology and more research is needed into the role of parathyroid hormone-related peptide as a growth factor and possibly target-directed monoclonal antibody therapies.\",\"PeriodicalId\":94009,\"journal\":{\"name\":\"Federal practitioner : for the health care professionals of the VA, DoD, and PHS\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Federal practitioner : for the health care professionals of the VA, DoD, and PHS\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.12788/fp.0018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.12788/fp.0018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Hypercalcemia Is of Uncertain Significance in Patients With Advanced Adenocarcinoma of the Prostate.
Hypercalcemia in the setting of prostate cancer is rare with an uncertain pathophysiology and more research is needed into the role of parathyroid hormone-related peptide as a growth factor and possibly target-directed monoclonal antibody therapies.